<DOC>
	<DOCNO>NCT02026362</DOCNO>
	<brief_summary>To prove efficacy safety 'MASCT group ' superior 'non-treatment group ' patient undergone curative resection ( RFA operation ) hepatocellular carcinoma China .</brief_summary>
	<brief_title>Multiple Antigen Specific Cell Therapy ( MASCT ) Hepatocellular Carcinoma ( HCC ) Patients After Radical Resection Radio Frequency Ablation ( RFA ) .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . The patient diagnose hepatocellular carcinoma ( HCC ) ; 2 . The patient underwent radical operation HCC within 8 week enrollment ; 3 . The number tumors≤2； 4 . No cancer embolus main portal vein first branch , hepatic duct first branch , hepatic vein , inferior vena cava ; 5 . No portal lymph node metastasis； 6 . No extrahepatic metastasis ; 7 . Complete tumor resection without residual tumor surgical margin confirm enhanced CT MRI image within 4 week ( include 4 week ) radical operation ; 8 . If increase serum AFP level detect patient radical operation , AFP level return normal 8 week ; 9 . ChildPugh Score ≤9 ; 10 . ECOG Performance status ( ECOGPS ) ≤2 ; 11 . The expected survival time &gt; 2 year ; 12 . Tests blood , liver kidney meet follow criteria： WBC &gt; 3×109/L Neutrophil count &gt; 1.5×109/L Hemoglobin ≥85 g/L Platelet counts≥50×109/L PT normal The extend time ＜3s BUN≤1.5 time upperlimit , Serum creatinine≤ 1.5 time upperlimit 13 . Sign inform consent . 1 . Women pregnant breast feed plan pregnant 2 year ; 2 . Extrahepatic metastasis liver residual tumor ; 3 . Cancer embolus main portal vein first branch , Hepatic duct first branch , hepatic vein , inferior vena cava ; 4 . 6 month enrollment : period systemic continuous use immunomodulatory agent ( interferon , thymosin , traditional Chinese medicine ) long 3 month ; 5 . 6 month enrollment : period systemic continuous use immunosuppressive drug ( corticosteroid drug ) long 1 month ; 6 . Received cell therapy ( include NK , CIK , DC , CTL , stem cell therapy ) 6 month enrollment ; 7 . Positive HIV antibody HCV antibody ; 8 . Have history immunodeficiency disease autoimmune disease ( rheumatoid arthritis , Buerger 's disease , multiple sclerosis diabetes type 1 ) ; 9 . Patient suffer malignant tumor 5 year enrollment ( except skin cancer , localize prostate cancer cervix carcinoma ) ; 10. . Patients organ failure ; 11 . Patients serious mental disease ; 12 . Drug addiction 1year enrollment ( include alcoholic ) ; 13 . Participated clinical trial 3 month screen ; 14 . Other reason researcher think suitable .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>HCC</keyword>
	<keyword>DC</keyword>
	<keyword>CTL</keyword>
</DOC>